- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Perjeta Improves Survival in HER2-Positive Breast Cancer Patients
The monoclonal antibody extended survival by nearly 16 months compared to those in the control cohort.
In Madrid today, researchers presented new findings on the effectiveness of Perjeta (pertuzumab, Roche), a monoclonal antibody used in combination with other drugs to treat some types of breast cancer. The updated report on the CLEOPATRA trial supports that adding Perjeta to Herceptin and chemotherapy significantly extends survival in patients with Her2-overexpressing (Her2+) metastatic breast cancer.
The international randomized trial, funded by Roche, included over 800 women with advanced Her2+ disease. The study participants all took Herceptin (trastuzumab, an antibody) and docetaxel (a chemotherapy, usually sold as Taxotere) and, based on the randomization, also received infusions of Perjeta or a placebo. Overall survival among women who received Perjeta was extended by nearly 16 months, as compared to the control.
Over half of the women with Her2+ metastatic breast cancer who received all three drugs (Perjeta, Herceptin and chemotherapy) lived for over 4.5 years on the study. This result confirms and bolsters earlier results of CLEOPATRA study, published in the New England Journal of Medicine, which led to the FDA’s initial 2012 approval of Perjeta for use in metastatic breast cancer.
Read the report on Forbes: http://onforb.es/YBs686
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
